Seema Singh
Co-founder and Editor at The Ken
Not given up on Journalism, yet. Learning to lead, edit, write & report better. Co-founder, Editor & Writer @thekenweb. (Always hiring) Author: Mythbreaker
Articles
-
1 week ago |
the-ken.com | Seema Singh
Good morning [%first_name |Dear Reader%], For a long time, the US has been subsidising global innovation, spending more on research than any other country in absolute and relative terms. As Trump continues to throw one wrecking ball after another into the American scientific enterprise, other countries have woken up.
-
1 month ago |
the-ken.com | Neha Mehrotra |Seema Singh
On 20 May, India’s communications minister said the country would likely witness the fastest satellite communications rollout in the world. It was a strong signal to the bickering parties. After years of Indian telecommunication companies’ tooth-and-nail opposition, Starlink finally has a Letter of Intent from the government clearing the way for it to beam broadband from space. Unlike in the past, there was no uproar in the media; just a quiet admission of its imminent entry.
-
1 month ago |
the-ken.com | Seema Singh
Good morning [%first_name |Dear Reader%], From selling insurance to selling assurance. That's the chasm PB Fintech, the parent of Policybazaar, wants to cross by backing a new business in healthcare. It's a chasm because selling insurance is, fundamentally, a low-trust endeavour. Selling assurance, on the other hand, is a high-fidelity, high-trust exercise. You sell a dream of healthcare, and on equated monthly instalments (EMI).
-
1 month ago |
the-ken.com | Seema Singh
Good morning [%first_name |Dear Reader%], When big ships turn, they displace a lot of water. And the Danish giant Novo Nordisk is making a sharp turn. It's phasing out insulin, the life-saving drug that has been in the market for over 40 years, to make way for newer, better, and more expensive products. In India, some 11 million diabetics are on insulin, and Novo commands 60% of the nearly Rs 5,000 crore market.
-
1 month ago |
the-ken.com | Seema Singh
Good morning [%first_name |Dear Reader%], Drones are flying everywhere. During the Pahalgam terrorist attack last week. In the Ukraine-Russia warfare escalation this week. For drug surveillance on the borders; over farmlands in the Indian hinterland. One company that's making the most of drone buzz-iness is Optiemus Infracom, a 31-year-old firm that distributes and assembles electronic devices.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 3K
- Tweets
- 4K
- DMs Open
- No
The real reason why Jio-Airtel and Starlink struck a so-called commercial deal. The economics of it all don't make sense, I argue in my story today https://t.co/H6vDuaRTQn https://t.co/m3TMyHW4kz
PB Fintech’s hospital investment is a head-scratcher or a no-brainer? I write in Long & Short today: https://t.co/ssDCTX235R https://t.co/PKGOF2V3vD
Novo Nordisk and its two rival insulin giants are phasing out their insulin business in India. Biocon-Eris sees a windfall. But it's a humbling lesson in self-reliance for India. @sudeshna_ra & I write : https://t.co/rnmFsrSlXM https://t.co/7OzO3UHR0F